Novartis’ Failed Cholesterol Drug Trial Sends Ionis and Amgen Tumbling
Novartis' experimental drug Pelacarsen, developed with Ionis, failed to reduce cardiovascular events in a major trial. Novartis (NYSE:NVS) and Ionis (NASDAQ:IONS) shares dropped, as did Amgen (NASDAQ:AMGN) due to read-through concerns. Analysts had predicted peak sales of $3-6B for Pelacarsen. Amgen's similar drug, olpasiran, is still in trials. The failure raises questions about the effectiveness of Lp(a)-lowering drugs.
How this was made
The 30-second read
Why it matters
The negative result prompted immediate sell‑offs in three major pharma stocks, with broader implications for RNA‑based cardiovascular programs.
Market read
The trial outcome is a primary catalyst moving large‑cap pharma stocks and reshaping expectations for Lp(a) therapeutics.
What to watch
Potential for Novartis to pivot to other pipeline assets or re‑evaluate dosing strategies.
Background
First outcomes trial of an Lp(a)‑lowering therapy failed to demonstrate clinical benefit, shaking confidence in the entire class.
Ticker impact
Novartis shares fell >3% after its pelacarsen trial failed to show cardiovascular benefit.
Further downside pressure in the near term as investors reassess revenue expectations.
First‑in‑class outcomes trial failure is material for a large‑cap pharma with significant exposure.
Ionis stock dropped 10% as its partner’s failed trial hurt expectations for pelacarsen.
Continued weakness expected until pipeline progress is clarified.
Ionis is directly tied to the failed drug and saw an immediate price drop.
Amgen fell ~10% on the same day as the Novartis failure despite no new data on its own Lp(a) candidate.
Potential further decline if olpasiran data later disappoint, but may stabilize if confidence returns.
The move is a read‑through effect; no new company‑specific data released.
Market effects
Lowers optimism for the broader Lp(a) therapeutic class, affecting biotech peers.
European and US pharma indices may see modest drag from the news.
Highlights risk in RNA‑based cardiovascular drugs worldwide.
Counterpoint
Amgen’s distinct olpasiran design could still succeed, offering a buying opportunity on the dip.
Key entities
- companyNovartis AG
Swiss pharma leading the failed pelacarsen trial.
- companyIonis Pharmaceuticals
Partner that co‑developed pelacarsen.
- companyAmgen Inc.
Rival with Lp(a) candidate olpasiran.
